| Cat.No. | Name | Information |
|---|---|---|
| M40495 | ENB-004 | ENB-004 is an endothelin receptor ETB antagonist that can be used in studies related to solid tumors. |
| M40494 | RES-7011 | RES-7011 is an endothelin receptor ETB antagonist that may be used in studies related to cardiovascular disease. |
| M40493 | RES-701-2 | RES-701-2 is a cyclic peptide and an antagonist of the endothelin receptor ETB. |
| M40492 | K-8768 | K-8768 is an endothelin receptor ETB antagonist that can be used in studies related to heart failure. |
| M40491 | ENDG-4010 | ENDG-4010 is an endothelin receptor ETB agonist that can be used in tumor-related studies. |
| M40490 | IRL-1038 | IRL-1038 is a selective endothelin receptor ETB antagonist for studies related to cardiovascular disease. |
| M40488 | K-8794 | K-8794 is an endothelin receptor ETB antagonist that may be used in studies related to heart failure. |
| M40487 | RES-701-1 | RES-701-1 is an endothelin receptor ETB antagonist that can be used in studies related to cardiovascular disease. |
| M40485 | LAS-103 | LAS-103 is an endothelin receptor ETB antagonist that may be used in studies related to breast cancer. |
| M40484 | ENB-005 | ENB-005 is an endothelin receptor ETB antagonist that can be used in studies related to brain metastases. |
| M40483 | ENB-003 | ENB-003 is an endothelin receptor ETB antagonist that may be used in melanoma-related studies. |
| M40482 | VRP-1620 | VRP-1620 is an endothelin receptor ETB antagonist that may be used in studies related to breast cancer. |
| M29057 | A-192621 | A-192621 is a potent, nonpeptide, orally active and selective endothelin B (ETB) receptor antagonist with an IC50 of 4.5 nM and a Ki of 8.8 nM. The selectivity of A-192621 is 636-fold higher than ETA (IC50 of 4280 nM and Ki of 5600 nM). A-192621 promotes apoptosis in PASMCs. A-192621 alos causes elevation of arterial blood pressure and an elevation in the plasma ET-1 level. |
| M28967 | ZD-1611 | ZD-1611 is a potent, orally active, selective ETA receptor antagonist, used for the research of ischemic stroke. |
| M28942 | Sitaxsentan | Sitaxsentan (IPI 1040; TBC-11251) is a selective endothelin A (ETA) receptor antagonist. Antihypertensive. Sitaxsentan is used in treatment of chronic heart failure. IC50 value: Target: ETA receptor |
| M28888 | Tezosentan | Tezosentan (RO 610612) is an endothelin (ET) receptor antagonist, with pA2s of 9.5, 7.7 for ETA and ETB receptors, respectively. |
| M28831 | Darusentan | Darusentan (Lu-135252) is a selective endothelin receptor A (ET-A) receptor antagonist, which binds with a Ki of 1.4 nM to the ET-A receptor and a Ki of 184 nM to ET-B receptor, respectively with a 100-fold selectivity for ETA rather than ETB receptors. Darusentan competes for radiolabeled endothelin binding in rat aortic vascular smooth muscle cells (RAVSMs) membranes with single-site kinetics, exhibiting a Ki of 13 nM. |
| M25435 | BMS-193884 | BMS-193884 is a selective, orally active, and competitive ETA antagonist with 10000-fold greater affinity for the human ETA receptor (Ki=1.4 nM) than for the ETB receptor. |
| M13960 | Endothelin 1 (swine, human) (TFA) | Endothelin 1 (swine, human) (TFA) is a synthetic peptide with the sequence of human and swine Endothelin 1, which is a potent endogenous vasoconstrictor. Endothelin 1 acts through two types of receptors ETA and ETB. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
